In short
A Phase 2 clinical trial is underway to evaluate the efficacy and safety of VE202, a novel drug containing live bacterial strains, for the treatment of mild to moderate ulcerative colitis. This randomized, double-blind, placebo-controlled study aims to assess the potential benefits of VE202 in improving endoscopic response and overall patient outcomes.
At a glance
- Study Type
- Phase 2, randomized, double-blind, placebo-controlled clinical trial
- Drug Name
- VE202 (capsule containing multiple live bacterial strains)
- Target Condition
- Mild to moderate ulcerative colitis
- Primary Objectives
- 1. Evaluate efficacy in terms of endoscopic response at Day 56; 2. Assess safety of VE202
- Treatment Duration
- 8 weeks
- Key Inclusion Criteria
- - Ages 18-75; - Diagnosed UC for at least 3 months; - Active mild to moderate UC; - No prior biologic treatment for UC
- Key Exclusion Criteria
- - History of Crohn's disease; - Recent use of antibiotics, probiotics, or certain herbal preparations; - Active infections or other specified medical conditions
- Primary Endpoints
- 1. Endoscopic response rate at Day 56; 2. Treatment-related adverse events
What is VE202?
VE202 is an innovative medication being studied for the treatment of mild-to-moderate ulcerative colitis. It is a capsule containing live bacteria, specifically designed to help restore balance to the gut microbiome. The drug is also known by its alternative name, JNJ-72537634.
How VE202 Works
VE202 is a unique combination of live bacterial strains that belong to various clusters of Clostridia and Bacilli. These bacteria are believed to play a crucial role in maintaining a healthy gut environment. By introducing these beneficial bacteria, VE202 aims to restore balance to the gut microbiome, which may help reduce inflammation and improve symptoms of ulcerative colitis.
The drug contains multiple strains of bacteria, including:
- Clostridia strains from clusters XIVA and IV
- Bacilli strains from cluster XVIII
These bacterial strains are carefully selected to work together in promoting gut health.
Target Condition: Mild-to-Moderate Ulcerative Colitis
VE202 is being studied for the treatment of mild-to-moderate ulcerative colitis. Ulcerative colitis is a type of inflammatory bowel disease (IBD) that causes inflammation and ulcers in the lining of the large intestine (colon) and rectum. Symptoms can include diarrhea, abdominal pain, and rectal bleeding.
Clinical Trial Details
A Phase 2 clinical trial is currently underway to evaluate the effectiveness and safety of VE202 for patients with mild-to-moderate ulcerative colitis. This trial is a randomized, double-blind, placebo-controlled study, which means that participants are randomly assigned to receive either VE202 or a placebo, and neither the participants nor the researchers know who is receiving which treatment.
The main objectives of the trial are:
- To evaluate the efficacy of 8 weeks of treatment with VE202 in terms of endoscopic response at Day 56
- To evaluate the safety of VE202 throughout the study
Eligibility Criteria
To participate in the clinical trial, patients must meet certain criteria. Some key eligibility requirements include:
- Age between 18 and 75 years
- Diagnosed with ulcerative colitis for at least 3 months
- Active mild to moderate ulcerative colitis, as determined by specific medical criteria
- No previous treatment with certain types of medications for ulcerative colitis
There are also several exclusion criteria, such as a history of Crohn's disease, recent use of antibiotics or probiotics, and certain other medical conditions.
Potential Benefits
If proven effective, VE202 could offer several potential benefits for patients with mild-to-moderate ulcerative colitis:
- Improvement in symptoms such as diarrhea, abdominal pain, and rectal bleeding
- Reduction in inflammation of the colon
- A new treatment option for patients who have not responded well to other therapies
- Potential for fewer side effects compared to some existing treatments, as it uses naturally occurring bacteria
Safety Considerations
As with any new medication, safety is a primary concern in the clinical trial of VE202. The study is designed to carefully monitor for any adverse effects. Some key safety considerations include:
- Monitoring for any treatment-related adverse events
- Assessing the occurrence of serious adverse events
- Evaluating the long-term safety of using live bacterial strains as a treatment
It's important to note that VE202 is still in the investigational stage, and its safety and efficacy have not yet been fully established. Patients interested in this treatment should discuss it with their healthcare provider and consider participating in clinical trials if eligible.